Cipla USA, Inc. recalls Nilotinib Capsules
- Published
- 11 Mar 2026
- Units affected
- 2 products
- Agency
- FDA
- Country
- United States
The hazard
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Classification: Class III — this product is unlikely to cause health problems but breaks FDA rules (for example labeling).
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17
Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17
- Brand / company
- Cipla USA, Inc.
- Codes / lots
- Lot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027 | Lot #: 5GJ0223, Exp 04/30/2027
- Distribution
- U.S.A. Nationwide
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 11 Mar 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.